149 related articles for article (PubMed ID: 6271510)
1. Is a circulating sodium transport inhibitor involved in the pathogenesis of essential hypertension?
MacGregor GA; de Wardener HE
Clin Exp Hypertens (1978); 1981; 3(4):815-30. PubMed ID: 6271510
[TBL] [Abstract][Full Text] [Related]
2. [Cytochemical demonstration of an endogenous inhibitor of Na-K ATPase and its relationship to familial arterial hypertension].
de Wardener H
Nephrologie; 1987; 8(1):3-6. PubMed ID: 3035398
[TBL] [Abstract][Full Text] [Related]
3. A circulating sodium transport inhibitor and essential hypertension.
MacGregor GA; de Wardener HE
J Cardiovasc Pharmacol; 1984; 6 Suppl 1():S55-60. PubMed ID: 6204160
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a raised concentration of a circulating sodium transport inhibitor in essential hypertension.
MacGregor GA; Fenton S; Alaghband-Zadeh J; Markandu N; Roulston JE; de Wardener HE
Br Med J (Clin Res Ed); 1981 Nov; 283(6303):1355-7. PubMed ID: 6274473
[TBL] [Abstract][Full Text] [Related]
5. The relation of a circulating sodium transport inhibitor (the natriuretic hormone?) to hypertension.
de Wardener HE; MacGregor GA
Medicine (Baltimore); 1983 Sep; 62(5):310-26. PubMed ID: 6312247
[TBL] [Abstract][Full Text] [Related]
6. The relation of the natriuretic hormone to essential hypertension.
de Wardener HE; MacGregor GA
Postgrad Med J; 1983; 59 Suppl 2():74-7. PubMed ID: 6310538
[TBL] [Abstract][Full Text] [Related]
7. Ouabainlike Na+,K+-ATPase inhibitor in the plasma of normotensive and hypertensive humans and rats.
de Wardener HE; Millett J; Holland S; MacGregor GA; Alaghband-Zadeh J
Hypertension; 1987 Nov; 10(5 Pt 2):I52-6. PubMed ID: 2824366
[TBL] [Abstract][Full Text] [Related]
8. An increase in a circulating inhibitor of Na+,K+-dependent ATPase: a possible link between salt intake and the development of essential hypertension.
MacGregor GA; Fenton S; Alaghband-Zadeh J; Markandu ND; Roulston JE; de Wardener HE
Clin Sci (Lond); 1981 Dec; 61 Suppl 7():17s-20s. PubMed ID: 6274566
[TBL] [Abstract][Full Text] [Related]
9. [Circulating inhibitor of the Na+-K+ pump in essential hypertension. Physiological and pharmacological variations].
Pernollet MG; de Thé H; Delva P; Wauquier I; Devynck MA; Baudouin-Legros M; Deray G; Rosenfeld J; Meyer P
Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1283-7. PubMed ID: 6098238
[TBL] [Abstract][Full Text] [Related]
10. Raised sodium pump activity and a circulating sodium transport inhibitor demonstrated on red blood cells of patients with untreated essential hypertension: correlation of pump activity with potassium permeability.
Skrabal F; Hamberger L; Cerny E; Schönegger J; Gernhold M
Klin Wochenschr; 1985; 63 Suppl 3():117-21. PubMed ID: 2987607
[TBL] [Abstract][Full Text] [Related]
11. Circulating inhibitors of sodium transport at the prehypertensive stage of essential hypertension.
Haupert GT
J Cardiovasc Pharmacol; 1988; 12 Suppl 3():S70-6. PubMed ID: 2467109
[TBL] [Abstract][Full Text] [Related]
12. The role of a circulating inhibitor of Na+-K+-ATPase in essential hypertension.
de Wardener HE; MacGregor GA
Am J Nephrol; 1983; 3(2-3):88-91. PubMed ID: 6307047
[No Abstract] [Full Text] [Related]
13. [The activity and properties of Na,K-ATPase in the erythrocytes and the Na-pump inhibitor in the plasma of subjects with borderline arterial hypertension].
Maslova MN; Ogorodnikova LE; Titkov IuS
Fiziol Zh SSSR Im I M Sechenova; 1991 Sep; 77(9):232-7. PubMed ID: 1666609
[TBL] [Abstract][Full Text] [Related]
14. The role of endogenous inhibition of Na-K-ATPase in human hypertension--sodium pump activity as a determinant of peripheral vascular resistance.
Kramer HJ; Glänzer K; Sorger M
Clin Exp Hypertens A; 1985; 7(5-6):769-82. PubMed ID: 2990771
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biochemical approach of a circulating Na+-pump inhibitor.
Devynck MA; de The H; Pernollet MG; Cloix JF; Rosenfeld JB; Kamal LA; Meyer P
J Physiol (Paris); 1984; 79(6):538-41. PubMed ID: 6152634
[TBL] [Abstract][Full Text] [Related]
16. Digitalislike circulating factor in hypertension: potential messenger between salt balance and intracellular sodium.
Haddy FJ
Cardiovasc Drugs Ther; 1990 Mar; 4 Suppl 2():343-9. PubMed ID: 2176807
[TBL] [Abstract][Full Text] [Related]
17. A circulating Na+-K+ATPase inhibitor, erythrocyte sodium transport and hypertension in patients with chronic renal failure.
Kariya K; Sano H; Yamanishi J; Saito K; Furuta Y; Fukuzaki H
Clin Exp Hypertens A; 1986; 8(2):167-83. PubMed ID: 2424645
[TBL] [Abstract][Full Text] [Related]
18. Studies on the role of sodium- and potassium-activated adenosine triphosphatase inhibition in the pathogenesis of human hypertension. Changes in vascular and cardiac function following inhibition of the sodium pump in normotensive subjects and effects of calcium entry blockade.
Kramer HJ; Glänzer K; Freitag T; Schönfeld J; Sorger M; Schlebusch H; Düsing R; Krück F
Klin Wochenschr; 1985 Jan; 63(1):32-6. PubMed ID: 2579261
[TBL] [Abstract][Full Text] [Related]
19. Na+, K(+)-ATPase inhibition and intracellular electrolyte content in essential and secondary hypertension.
Spieker C; Zidek W; Rahn KH
Am J Hypertens; 1991 Apr; 4(4 Pt 1):309-14. PubMed ID: 1647795
[TBL] [Abstract][Full Text] [Related]
20. Cytochemically detectable glucose-6-phosphate dehydrogenase-stimulating/Na-K-ATPase-inhibiting activity of plasma and hypothalamus in reduced renal mass hypertension.
Holland S; Millett J; Alaghband-Zadeh J; de Wardener H; Pamnani M; Haddy F
Am J Hypertens; 1991 Apr; 4(4 Pt 1):315-20. PubMed ID: 1647796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
